Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Risk of TB Higher for Patients Taking Infliximab, Adalimumab, Than Etanercept - (DGNews)
    Golimumab Effective in Patients With RA Who Have Poor Response to Other Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/25/2009 - (DGNews)
    Initial Therapy With Adalimumab Plus Methotrexate Leads to Better Outcomes Over 5 Years in Patients With Early Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept Plus Methotrexate Safe, Effective for Up to 5 Years in Patients With Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis
    • Safety of Novel Immunomodulatory Therapies
      Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      New Recommendations for Disease-Modifying Antirheumatic Drugs and Emerging Options for the Treatment of Rheumatoid Arthritis
      Failing a TNF Inhibitor: What About Switching?

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Autologous Chondrocyte Implantation for Rheumatoid Arthritis of the Knee: A Case Report
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report
        Aseptic Meningitis in a Patient Taking Etanercept for Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Infliximab May Induce Antinuclear Antibodies

        A DGReview of :"Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy"
        Arthritis & Rheumatism

        05/12/2003
        By David Loshak


        The monoclonal antibody infliximab may induce antinuclear antibodies -- especially IgM and IgA anti-double stranded DNA antibodies -- in patients with rheumatoid arthritis and spondyloarthropathy, according to research conducted at Ghent University Hospital, Belgium.

        The study showed no anti-double stranded DNA IgG antibodies and signs or symptoms of lupus over the 30-34 weeks of infliximab treatment.

        However, the researchers emphasise, further follow-up is essential because their findings did not exclude potential long-term induction of clinically significant lupus.

        They investigated the effect of infliximab on antinuclear antibodies, anti-double-stranded DNA, antinucleosome, antihistone and anti-extractable nuclear antigen antibodies in 62 patients with rheumatoid arthritis and 35 with spondyloarthropathy. All were tested at baseline and at week 30 (rheumatoid arthritis) or week 34 (spondyloarthropathy).

        Initially, 32 of the rheumatoid arthritis patients tested positive for antinuclear antibodies but after infliximab treatment 51 patients tested positive (P<0.001). Likewise, the number of spondyloarthropathy patients testing positive increased from six at baseline to 31 at 34-week follow-up (P<0.001).

        At baseline, no patient in either group had anti-double stranded DNA antibodies, but after infliximab treatment, seven rheumatoid arthritis patients and six spondyloarthropathy patients tested positive(P=0.016 and P=0.031 respectively).

        All seven rheumatoid arthritis patients who were positive for anti-double stranded DNA had IgM and IgA anti-double stranded DNA antibodies. In the spondyloarthropathy group, that number, three of six had IgM and IgA anti-double stranded DNA antibodies, and two had IgM anti-double stranded DNA antibodies alone.

        In both groups, the IgM anti-double stranded DNA antibodies appeared before the IgA anti-double stranded DNA antibodies.

        Although some patients who were treated with infliximab developed antibodies to antinucleosome, antihistone and anti-ENA, the numbers were not statistically significant, the researchers note.
        Arthritis Rheum 2003 Apr;48:4:1015-23. "Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send